Please turn JavaScript on
header-image

BioPharma Dive - Latest News

Subscribe to BioPharma Dive - Latest News’s news feed.

Click on “Follow” and decide if you want to get news from BioPharma Dive - Latest News via RSS, as email newsletter, via mobile or on your personal news page.

Subscription to BioPharma Dive - Latest News comes without risk as you can unsubscribe instantly at any time.

You can also filter the feed to your needs via topics and keywords so that you only receive the news from BioPharma Dive - Latest News which you are really interested in. Click on the blue “Filter” button below to get started.

Title: BioPharma Dive - Latest News

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  2.67 / day

Message History

Sales of Casgevy, a gene-edited treatment developed with CRISPR Therapeutics, more than tripled compared to the third quarter, a performance analysts saw as a bright spot in Vertex's report.


Read full story

Lyell’s trial will test its experimental cancer cell therapy directly against marketed counterparts. Elsewhere, venture firms are joining up at a “pivotal time” for Europe and Biogen swapped board chairs.


Read full story

The FDA has lifted longstanding and the most severe warnings off of hormone replacement therapies for menopausal women.


Read full story

The mRNA specialist reiterated its financial estimates for 2026 amid a challenging U.S. regulatory environment where its influenza vaccine just hit a major setback.


Read full story

Neurocrine and Alnylam each face investor questions about the growth potential of key franchises. Ascendis, meanwhile, saw an upbeat sales report overshadowed by the progress of an emerging rival. 


Read full story